158 related articles for article (PubMed ID: 33433422)
1. Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment.
Pasricha S; Grover S; Kamboj M; Bansal D; Batra U; Gupta G; Sharma A; Durga G; Jajodia A; B Koyyala VP; Mehta A
Indian J Pathol Microbiol; 2021; 64(1):128-131. PubMed ID: 33433422
[TBL] [Abstract][Full Text] [Related]
2. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.
Xu K; Gao J; Feng L; Fang Y; Tang X
Front Immunol; 2023; 14():1203876. PubMed ID: 37292208
[TBL] [Abstract][Full Text] [Related]
3. Arginase-1 is frequently positive in hepatoid adenocarcinomas.
Chandan VS; Shah SS; Torbenson MS; Wu TT
Hum Pathol; 2016 Sep; 55():11-6. PubMed ID: 27137985
[TBL] [Abstract][Full Text] [Related]
4. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases.
Terracciano LM; Glatz K; Mhawech P; Vasei M; Lehmann FS; Vecchione R; Tornillo L
Am J Surg Pathol; 2003 Oct; 27(10):1302-12. PubMed ID: 14508391
[TBL] [Abstract][Full Text] [Related]
5. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature.
Haninger DM; Kloecker GH; Bousamra Ii M; Nowacki MR; Slone SP
Mod Pathol; 2014 Apr; 27(4):535-42. PubMed ID: 24030743
[TBL] [Abstract][Full Text] [Related]
6. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
11. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
13. About PD-L1 Immunohistochemistry and RNA In Situ Hybridization in Lung Adenocarcinoma.
Uguen A
Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):e9-e10. PubMed ID: 29494400
[No Abstract] [Full Text] [Related]
14. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
15. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Lee SE; Kim YJ; Sung M; Lee MS; Han J; Kim HK; Choi YL
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561631
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W
Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
18. Hepatoid adenocarcinoma of the lung: Review of a rare form of lung cancer.
Grossman K; Beasley MB; Braman SS
Respir Med; 2016 Oct; 119():175-179. PubMed ID: 27692141
[TBL] [Abstract][Full Text] [Related]
19. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
20. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
